Compulsory Licensing under Indian Patent Law: Balancing Patent Rights and Public Interest
Introduction : Patent law gives proprietary or exclusive rights to inventors over their inventions for a certain time period. These rights provide the patent owner with control of the use, manufacture and sale of the invention. Patent protection is there to promote innovation and investment in R&D. This is particularly important in sectors like pharmaceuticals that consume huge sums of money and time in developing medicines and medical technology. Patent rights, however, are not absolute. However, in certain cases, public access to patented products at low prices may be required, especially when it comes to medicines and healthcare. When this is the case, the monopoly held by patent holders can pose problems for the general public. Indian patent law adopts the doctrine of compulsory licensing to strike a balance between these interests. In such a system, others might legally use and/or produce a patented invention in certain specified situations without the owner’s permission. This concept gained enormous significance in India during the discussion on availability of inexpensive drugs and public health. This article discusses the concept of compulsory licensing, relevant laws and the stance taken by the Indian judicial system and authorities in response to such situations.
Meaning of Compulsory Licensing
In general, compulsory licensing is a situation under which a third party is provided the right without the patent holder’s consent by the government or a competent authority, to use a patented invention. This does not imply that the patent gets cancelled. The rights for ownership of the patent still stay with the initial patent holder, but the provision allows that the patent may be used or made by someone else under specific situations. The simple rationale of compulsory licensing is that patents should not be used in a manner detrimental to public interest. Patent protection gives incentives for innovation with a view to the benefit of society. There can be issues when the patented product is sold at a very high price, when reasonable requirements of the public are not met. In such cases, compulsory licensing provides protection. This concept has gained significance against a background of medicines as access to healthcare has significant impact on public welfare. This issue is therefore not only connected with patent law but also with larger concerns relating to public health and affordability.
Position under the Patents Act, 1970
The provisions relating to compulsory licensing are mainly contained in Section 84 of the Patents Act, 1970. It provides compulsory licensing under specific conditions after 3 years of the patent grant for anyone who has an interest. One is that the reasonable needs of the public with regard to the patented invention have not been fulfilled. The second ground is that the patented invention cannot be sold to the public for a price that is “reasonably affordable”. The third ground is that the patented invention does not work in India. The case can be cited to illustrate the fact that Indian patent law is not based on the idea of holding patents for no public advantage. The law requires patentees to maintain availability and accessibility of their invention. Compulsory licensing can then be utilized as a tool of ensuring the public interest in situations where patents are being used in an exclusionary way. Indian patent law works toward balancing interest of the inventor and availability of these important products to the public without causing any harm to them.
Bayer Corporation vs. Natco Pharma Ltd.
Bayer Corporation v. Natco Pharma Ltd. is one of the most important cases addressing the issue of compulsory licensing in India. In this case, Bayer’s drug Nexavar, a treatment for cancer, was involved. The price of the medicine was very high and as a result, many patients find it difficult to obtain the medicine. Natco Pharma filed an application for compulsory licensing under Section 84 of Patents Act. The reason given by the Controller for granting the compulsory license on the main grounds is the medicine was not available at a reasonably affordable price; the reasonable requirements of the public were not met. The Controller further noted that the patented invention was not being adequately worked in India. This was the first compulsory license given in India under the Patents Act, 1970. Oral anti-anginal drugs and medicines for anaemia were the focus of this case, which attracted international interest due to the conflict within the patent protection/defect access framework. There were arguments that public health issues should be seen more seriously, particularly in the less developed countries. Meanwhile, pharmaceutical firms and foreign entities decried the move and have suggested that too much compulsory licensing would deter innovation and investment in R&D.
Public Interest and Access to Medicines
The public interest and access to medicines are closely intertwined with compulsory licenses. In developing nations such as India, many people rely on inexpensive medicine for diagnosis and treatment because many people cannot afford them easily, then there may be difficulties accessing health care to ensure access for many people. Indian patent law thus makes an effort to prevent the harmful effects on the public interest caused by patent rights. During all of this, the pharmaceutical companies are saying that developing a drug takes plenty of money, a lot of scientific work and many years into human trials. They say that good patent protection is essential to recoup investments and spur innovation. For this reason, compulsory licence is something that both legal and economic issues are important to contemplate. Overcharging of patent rights can be associated with reduction of investments and innovations, and overprotection of patent monopolies with reduction of access to essential medicines for the public. Indian law thus strives for a middle ground between these conflicting interests.
Role of the Indian Patent Office
The Indian Patent Office is a key organization to analyze applications for compulsory licences. The law’s conditions outlined in Section 84 should be considered with care to determine if they are met. The process may be complicated due to the technical and scientific nature or the detailed economic discussions of many patent conflicts. Affordability, availability of medicines, manufacturing capability and public needs are among the considerations which may be taken into account by the examining and other authorities. In certain circumstances, the claims for patent holders might be different as they say that they have already complied with the public need, whereas the applicants who want compulsory licensing may say otherwise. The issue of compulsory licensing may, therefore, be subject to multiple considerations in making decisions. However, the role of the Patent Office is crucial in making sure that patent law serves overall innovation and public interests.
Practical Difficulties
Though compulsory licensing is available under Indian law, there are still some practical problems. A difficulty also is that the definition of a “reasonably affordable price” might not always be readily apparent. Various parties can have varying views of what is affordable and what the public needs. Another issue is that compulsory licensing often leads to international criticism and trade-related concerns. Drug manufacturers occasionally claim that this causes uncertainty to investors and innovators. In addition, in most patent litigation cases, there are delays in the procedure and protracted litigation. Pharmaceutical patent litigation typically also requires evidence of a technical and scientific nature; court actions can proceed for an extended period of time. There could also be future challenges due to the technological advances and growing healthcare needs. For the aforementioned reasons, compulsory licensing remains a significant and controversial aspect of Indian patent regimes.
Conclusion
The right of compulsory licensing will continue to play an important role in Indian patent law, particularly in the field of medicines and healthcare. The Patents Act, 1970 tries to achieve a balance between the need for patent protection and the public interest by enabling patent rights not to be exercised in a manner which interferes with access to essential products. Therefore, Section 84 is significant in the interest of public welfare because patented inventions are not available or are too costly, have not actually been worked much in India, or their working has been insufficient in India. The Bayer Corporation V. Natco Pharma Ltd. case is a landmark ruling that brought to light India’s attitude in striking a balance between innovation and access to medicines. Meanwhile, compulsory licensing remains a topic for debate on innovation, investment, and public health issues. With the evolution of medical needs and the technology of medicines, compulsory licensing will be expected to be a relevant topic in Indian Patent Law.
Author:- Ayushman Bhatt, in case of any queries please contact/write back to us at support@ipandlegalfilings.com or IP & Legal Filing.
References
- The Patents Act, 1970, § 84, Government of India.
- Bayer Corporation v. Natco Pharma Ltd., Controller of Patents, 2012.
- TRIPS Agreement, World Trade Organization.
- Office of the Controller General of Patents, Designs and Trade Marks, Manual of Patent Office Practice and Procedure.
- World Intellectual Property Organization (WIPO), Public Health and Patents.